Risk Factors Update Summary
- Research expenses expected to increase significantly from $29 million to $18 million.
- Plans to suspend the launch of the imatinib Phase 3 trial in PAH.
- Nasdaq compliance period extended to March 2024 due to bid price rule non-compliance.
- Net operating losses decreased from $11.0 million to $8.2 million in 2023.
- Commitment to maintain compliance to retain listing amidst global uncertainties and regulatory challenges.
- Potential collaborations with third parties to advance product candidates and mitigate delays.
- Dependence on third-party suppliers and CMOs for manufacturing, with a 24-month notice provision.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=34956&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.